Analyst Price Targets — SABS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 6:01 am | Michael Yee | UBS | $7.00 | $3.62 | StreetInsider | UBS Starts SAB Biotherapeutics (SABS) at Buy |
| September 17, 2025 10:58 am | — | Leerink Partners | $7.00 | $2.58 | TheFly | SAB Biotherapeutics initiated with an Outperform at Leerink |
| June 7, 2024 3:45 am | Kumaraguru Raja | Loop Capital Markets | $8.00 | $2.84 | StreetInsider | Brookline Capital Markets Starts SAB Biotherapeutics (SABS) at Buy |
| April 2, 2024 6:44 am | Edward White | H.C. Wainwright | $6.00 | $4.29 | StreetInsider | SAB Biotherapeutics (SABS) PT Lowered to $6 at H.C. Wainwright following Q4 report |
| August 11, 2022 7:41 am | — | Chardan Capital | $3.00 | $1.12 | Benzinga | Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $3 |
Latest News for SABS
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-142 showed improved glycemic control MIAMI, April 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin…
SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candidate targeting both stage 2 and stage 3 patients. SAB-142 may preserve beta-cell function and C-peptide with a cleaner safety profile than animal-derived immune therapies, supporting potential repeat dosing. The registrational Phase 2b SAFEGUARD study is the key value driver, while broader autoimmune programs provide…
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common…
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the pricing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common…
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock (and, in lieu of common stock to certain investors, pre-funded warrants…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SABS.
U.S. House Trading
No House trades found for SABS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.